<DOC>
	<DOCNO>NCT02607800</DOCNO>
	<brief_summary>This study evaluate safety efficacy treatment sofosbuvir/velpatasvir/voxilaprevir ( SOF/VEL/VOX ) SOF/VEL adult chronic HCV infection previously receive treatment direct-acting antiviral therapy .</brief_summary>
	<brief_title>Safety Efficacy Sofosbuvir/Velpatasvir/Voxilaprevir Sofosbuvir/Velpatasvir Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Willing able provide write informed consent HCV RNA ≥ 10^4 IU/mL screen Chronic HCV infection ( ≥ 6 month ) HCV treatment naive treatment experience interferon ( IFN ) base regimen Use protocol specify method contraception Key Current prior history clinically significant illness may interfere participation study Screening ECG clinically significant abnormality Laboratory parameter outside acceptable range screen Pregnant nursing female Chronic liver disease cause HCV Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic Hepatitis C Infection</keyword>
</DOC>